Skip to content
Sign in
Artwork for Hematologic Oncology Update
Hematologic Oncology Update · November 4 · 1 hr 1 min

Diffuse Large B-Cell Lymphoma — A Grand Rounds Program

Featuring a presentation by Dr Matthew Matasar, including the following topics: Selection of First-Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) (0:00) Clinician Survey Results Regarding First-Line Treatment of DLBCL (11:41) Current and Future Roles of Monoclonal and Bispecific Antibodies in Therapy for Relapsed/Refractory (R/R) DLBCL (16:01) Clinician Survey Results Regarding the Use of Monoclonal and Bispecific Antibodies for R/R DLBCL (28:47) Evidence-Based Incorporation of Antibody-Drug Conjugates (ADCs) into the Management of R/R DLBCL (34:34) Clinician Survey Results Regarding the Use of ADCs for R/R DLBCL (46:31) Discussion of Questions from the Community (50:20) CME information and select publications

0:00 · Selection of First-Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL)-1:01:39
Play in

transcript

No transcript — this publisher did not publish one.

show notes

Featuring a presentation by Dr Matthew Matasar, including the following topics:

  • Selection of First-Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) (0:00)
  • Clinician Survey Results Regarding First-Line Treatment of DLBCL (11:41)
  • Current and Future Roles of Monoclonal and Bispecific Antibodies in Therapy for Relapsed/Refractory (R/R) DLBCL (16:01)
  • Clinician Survey Results Regarding the Use of Monoclonal and Bispecific Antibodies for R/R DLBCL (28:47)
  • Evidence-Based Incorporation of Antibody-Drug Conjugates (ADCs) into the Management of R/R DLBCL (34:34)
  • Clinician Survey Results Regarding the Use of ADCs for R/R DLBCL (46:31)
  • Discussion of Questions from the Community (50:20)

CME information and select publications

links1

chapters

7 chapters

more episodes

All episodes